Amicus Therapeutics (FOLD)
(Real Time Quote from BATS)
$6.88 USD
+0.05 (0.73%)
Updated Aug 5, 2025 10:10 AM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FOLD 6.88 +0.05(0.73%)
Will FOLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Other News for FOLD
JPMorgan Increases Price Target for Amicus Therapeutics (FOLD)
Amicus price target raised by $2 at JPMorgan, here's why
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ...
Q2 2025 Amicus Therapeutics Inc Earnings Call Transcript
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200